Amarin Announces Notification of Patent Allowances for U.S. Applications Related to Vascepa and FDA Approved MARINE Indication
Amarin Corporation (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notices of Allowance for two additional U.S. Patent Applications, Serial Numbers 12/702,889 and 13/349,153. These applications include claims intended to protect the Vascepa (icosapent ethyl) indication approved in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application.
The issued patents would have terms that expire no earlier than in 2030. After issuance, Amarin plans to list both patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.